Glenmark gets USFDA approval for generic drug Tarka
New Delhi, February 26, 2015: Glenmark Pharmaceuticals has received approval from the US health drug regulator to sell the generic version of AbbVie Inc's blood pressure drug Tarka in the US market.
It may be noted here that the approval for trandolapril and verapamil hydrochloride extended release tablets has been granted to Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd.
The company said in a filing to the BSE that it will commence distribution of trandolapril and verapamil hydrochloride tablets immediately. These will be available in strengths of 1mg/240mg, 2mg/180 mg, 2mg/240mg and 4mg/240 mg.
The drug is indicated for the treatment of hypertension. The company has said that according to the IMS Health data, the drug sales of Tarka stood at around US$ 23.5 million for the 12 month period ending December 2014.
Glenmark currently has a portfolio of 95 products authorised for distribution in the US and 74 ANDA's pending approval with the US Health regulator.